Archives
-
SD 169: Selective p38 MAPK Research Guide
2026-09-11
SD 169, also called indole-5-carboxamide, is a selective ATP-competitive inhibitor of p38α and p38β MAPKs. Product evidence supports its use as a research tool in type 1 diabetes research, Schwann-cell biology, axonal regeneration research, and pathway-focused apoptosis assay development.
-
TET2 Metabolite Binding: Methods and Findings
2026-09-11
This 2025 STAR Protocols study presents an orthogonal workflow that combines biochemical activity assays with saturation transfer difference NMR to validate metabolite binding and regulation of human TET2. The protocol distinguishes activating and inhibitory metabolites while offering practical safeguards against interpreting activity changes without direct evidence of molecular interaction.
-
NF 449 for P2X1 Platelet Research
2026-09-10
NF 449 helps researchers isolate ATP-driven P2X1 signaling from broader platelet purinergic responses. This practical guide connects receptor-selective assay design with collagen-induced platelet aggregation, translational thrombosis models, and troubleshooting strategies.
-
SIS3 Smad3 Inhibitor: Research Workflow Guide
2026-09-10
SIS3 enables selective interrogation of Smad3-dependent TGF-β signaling without intentionally blocking Smad2 phosphorylation, making it useful for fibrosis, renal, and mechanistic cancer assays. This guide translates pathway biology into practical dosing, controls, readouts, and troubleshooting steps while distinguishing established evidence from hypothesis-generating applications.
-
Silybin A Workflows for Silymarin Metabolism
2026-09-09
Build reproducible Silybin A assays for oxidative stress, hepatoprotection, and adipocyte–liver metabolic research. A factorial workflow separates compound effects from adipocyte-targeted CRISPRi, revealing where Silymarin-derived chemistry complements gene silencing and where evidence remains preliminary.
-
Leucomycin (Kitasamycin): From Mechanism to Translation
2026-09-09
Leucomycin (kitasamycin) is more than a macrolide benchmark: its ribosome-directed activity, multicomponent composition, and resistance-linked rRNA biology create a practical framework for translational inhibition studies, analytical control, and antibacterial drug discovery.
-
Dabigatran Etexilate: Oral Direct Thrombin Inhibition
2026-09-09
The reference review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its prodrug design, rapid and predictable anticoagulant activity, and reduced dependence on INR-guided management. Its practical value is balanced against bleeding risk, gastrointestinal effects, and the need for renal-function-based dose adjustment.
-
Bsa I (RNase-free): DNA Workflow Guide
2026-09-08
Bsa I (RNase-free) provides sequence-specific DNA cleavage for cloning, DNA manipulation, and other molecular biology research workflows where RNA degradation must be minimized. It is intended for scientific research only and should not be used for diagnostic, clinical, or medical applications.
-
Targeted SPP1 Inhibition Reprograms TAMs
2026-09-07
Kartal and colleagues developed a macrophage phenotypic screen to identify small-molecule modulators that reduce SPP1 expression, then incorporated promising hits into a TAM-avid CANDI nanoformulation. The lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions across murine models, supporting targeted myeloid reprogramming as a therapeutic strategy.
-
Angiotensin III: A RAAS Assay Interpretation Guide
2026-09-07
Angiotensin III is more than a downstream RAAS metabolite: it is a useful probe for aldosterone, receptor signaling, and pressor biology. This guide connects A1043 product characterization with emerging spike–AXL binding evidence while clarifying assay design and interpretation limits.
-
Sex Differences in Angiotensin II Hypertension
2026-09-05
Xue, Pamidimukkala, and Hay used radiotelemetry in conscious mice to show that chronic angiotensin II produces a substantially stronger hypertensive response in males than in females, despite comparable baseline blood pressure. Gonadectomy, baroreflex testing, and ganglionic blockade connected this divergence with sex-dependent hormonal and sympathetic regulation, providing a useful framework for studying hypertension as a biological-sex-dependent phenotype.
-
Angiotensin III Workflow for RAAS Research
2026-09-04
Build reproducible RAAS assays around Angiotensin III, from receptor profiling and aldosterone-release experiments to controlled pressor models. Its defined sequence, high HPLC purity, strong solvent compatibility, and emerging relevance to spike–receptor binding make it a practical bridge between cardiovascular and mechanistic ligand research.
-
Nile Red: Lipid Droplet Imaging Guide
2026-09-04
Nile Red, also called Nile blue oxazone, is a lipophilic fluorescent probe for visualizing intracellular lipid droplets. Its environment-sensitive red and green fluorescence supports lipid distribution imaging, but fluorescence intensity alone does not establish lipid flux or a disease mechanism.
-
NF 449 for Reliable Platelet Assays
2026-09-03
This scenario-based guide explains how NF 449 (SKU B6716) can clarify ATP-sensitive platelet signaling while helping researchers distinguish pathway modulation from nonspecific cytotoxicity. It covers assay design, preparation, potency interpretation, and practical criteria for selecting a reliable research-grade reagent.
-
AZD0156 ATM Kinase Inhibitor Workflows
2026-09-03
AZD0156 enables selective ATM pathway interrogation across acute signaling, DNA double-strand break repair, and combination-response assays. This workflow-focused guide covers formulation, dose design, orthogonal readouts, metabolic extensions, and troubleshooting for reproducible cancer therapy research.